Afuresertib (GSK2110183)

Catalog No.S7521

For research use only.

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Afuresertib (GSK2110183) Chemical Structure

CAS No. 1047644-62-1

Selleck's Afuresertib (GSK2110183) has been cited by 20 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Other Akt Products

Biological Activity

Description Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
0.08 nM(Ki) 2 nM(Ki) 2.6 nM(Ki)
In vitro

Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MmG2SpVv[3Srb36gZZN{[Xl? NUDVc|B5PDBibXnudy=> NHjWZYJKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIFHLWFEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5ic4Xid5Rz[XSnIIDoc5NxcG:{eXzheIlwdiC3c3nu[{BjcW:2aX6tZYh5NUGUS2LFVmF[W0[JSFjBMYFucWSnIIP1ZpN1emG2ZTDhcoQhY2ejbX3hMVM{WF2DVGCgbY5kfWKjdHXkJIZweiB2MDDtbY5{KGK7IITvdEBkd3WwdDDtbYNzd3CuYYTlJJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMEGg{txONg>? NWThXYd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
Sf9 NIf5TpJHfW6ldHnvckBie3OjeR?= NVvaeohmPDBibXnudy=> MlG3TY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDoeY1idiCDS2SzJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHO3YoP0doF1\SCyaH;zdIhwenmuYYTpc44hfXOrbnegZolwfGmwLXHofE1CWkuURWLBXXNHT0iKQT3hcYll\SC|dXLzeJJifGViYX7kJHto[W2vYT2zN3BeSVSSIHnuZ5Vj[XSnZDDmc5IhPDBibXnud{BjgSC2b4CgZ492dnRibXnjdo9xdGG2ZTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODBzNUi1JO69VS5? MkPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
COLO205 MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYHHNZRyPzJiaILz MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU2xQOjB3IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{AtKEmFNUCgQUAxNjByOTFOwG0v NHO0T5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Sf9 MonWSpVv[3Srb36gZZN{[Xl? NHzW[nc1OCCvaX7z NV[2dnNSUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDBT3QzKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIIP1ZpN1emG2ZTDwbI9{eGixconsZZRqd25idYPpcoch[mmxdHnuMYFpgC2DUlvSSXJCYVOIR1jIRU1idWmmZTDzeYJ{fHKjdHWgZY5lKFupYX3tZU0{O1CfQWTQJIlv[3WkYYTl[EBnd3JiNECgcYlveyCkeTD0c5Ah[2:3boSgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMEGg{txONg>? NFu0ZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
MV522 Mk\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnvOO|IhcHK| MnjPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY2OjJiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOTJizszNMi=> MlXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HT-29 M1Pq[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{CwdVczKGi{cx?= Mmq5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOTVizszNMi=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H727 NFKxWoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIfmbZo4OiCqcoO= MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDd{NzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjBzOTFOwG0v MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1417 NULZZ25uT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnH6O|IhcHK| NUHpTo1MT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNEG3JINmdGy|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyxiSVO1NEA:KDBwMEOg{txONg>? M2jmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
Calu6 MnnSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYi3NkBpenN? MlTFS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gR4FtfTZiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOzFizszNMi=> MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
LS1034 MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{DqWFczKGi{cx?= MlzsS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUHMyODN2IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODRizszNMi=> M2\Xd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
SW1463 MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYm3NkBpenN? NGXHe21Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzF2NkOgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yNEGg{txONg>? NWnSN2NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
RKO M1jN[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXaO|IhcHK| Mor2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVmtQKGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNFU1KM7:TT6= MnfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H508 M1OzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWm3NkBpenN? NUD5Tmg{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NFgh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO|IhcHK|LDDJR|UxKD1iMD6wPEDPxE1w M2XoUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
NCI-H1155 NYHoUnRyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mne5O|IhcHK| NVS3bHZLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{LDDJR|UxKD1iMD6xNFEh|ryPLh?= MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
A427 NVfLcYV6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYW3NkBpenN? M1HDNmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yODNizszNMi=> MljBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
KM12 Mo\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX23NkBpenN? Ml:wS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20yOiClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlExPCEQvF2u NUi2W|Z4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
HCT8 NELQXG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLVO|IhcHK| M4HFPGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDhiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yPDNizszNMi=> Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
MDA-MB-175-VII Mk\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXZO|IhcHK| M4j5cmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO|UuXkmLIHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOTV3IN88UU4> M13ESlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
A549 NX\JPVZFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXHFSnVFPzJiaILz M1PrTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yPjRizszNMi=> M3LndFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
NCI-H23 MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4q1d|czKGi{cx?= M1fXSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkOgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KCxiSVO1NEA:KDBwMUm5JO69VS5? M2G2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
SW837 NWfLS5VTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVn3WphDPzJiaILz NX\PbZVuT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6M{egZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5{NEig{txONg>? NGLMSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW480 M2f0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{D3blczKGi{cx?= M3nv[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhyIHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOjV7IN88UU4> NF\qU2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1355 MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTkWI04OiCqcoO= NFv3fFVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO|IhcHJuIFnDOVAhRSByLkK2PEDPxE1w M1TlXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
EFM19 NIrhUFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\RTYc4OiCqcoO= MlrjS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSWZOOTliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4{KM7:TT6= M33YXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
T84 NF\oRmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV[3NkBpenN? MmnlS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFg1KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuN|A1KM7:TT6= NWTIb|hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
COR-L23 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1v6dlczKGi{cx?= NHH6cnJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGy|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyBuIFnDOVAhRSByLkO2PEDPxE1w M3O4W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
NCI-H1792 M{[2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnQXGJSPzJiaILz M4HY[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpeixiSVO1NEA:KDBwM{e0JO69VS5? NGLTZ|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW1573 MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPnRXo4OiCqcoO= M3TQR2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYOTV5MzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjN6MjFOwG0v MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
Calu3 NILLUWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW[3NkBpenN? MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDZYx2OyClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlM6OiEQvF2u MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
HCC827 NILJ[mlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn[zO|IhcHK| M4DETWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhESzh{NzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjRyMTFOwG0v MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
EFM19 NGLRWYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHaO|IhcHK| M1XENGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGVHVTF7IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCwMlQ{KM7:TT6= NFfuWm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
HOP62 MlLXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUK3NkBpenN? NX3tcosxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SNkKgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC52OUig{txONg>? MkSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H508 Mo\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXq3NkBpenN? M3;obGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUC4JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjV{MjFOwG0v M{ezeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
SW900 MoPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkT1O|IhcHK| NFP2S|JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjdzOTFOwG0v NXS3VlhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
MDA-MB-175-VII MnPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHv[41oPzJiaILz M2DqbWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO|UuXkmLIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCwMlc6PCEQvF2u NEXRNYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1155 NX75V4FFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\IdFczKGi{cx?= M{\1emdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUG1OUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hOC56NkWg{txONg>? M1vR[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
DLD1 MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXS3NkBpenN? MkG2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSGxFOSClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlk{OiEQvF2u NGPlUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
HT-29 MkPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU[3NkBpenN? NUXBUGZ3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFEvOzh|IN88UU4> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
HCT8 M2\kc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MljDO|IhcHK| NEnGflRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1R6IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCxMlU1OSEQvF2u NITMVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
RKO MorQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWS3NkBpenN? NUK2T2RIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCxMlgxPiEQvF2u MoXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
Calu6 MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHL1Sno4OiCqcoO= NIiyUVBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3NjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG|c3H5MEBKSzVyIE2gNk4yPTRizszNMi=> NU\rS5RnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
KM12 MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPKUpQ4OiCqcoO= MoXDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20yOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDD[YxtNXSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR|UxKD1iMj6yOFch|ryPLh?= NYS2XXJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
COLO205 NULUU4VHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGnXWXM4OiCqcoO= NXrWSHhzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hOi53Nkeg{txONg>? NXXMZm9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
MV522 M17KWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWO3NkBpenN? MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWlUzOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDD[YxtNXSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR|UxKD1iMz6wOFQh|ryPLh?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
LS1034 NFfzW|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoL3O|IhcHK| NVnhV5ZVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVFNzMEO0JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA1NjN|OTFOwG0v NULNeFhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H727 NG[2b|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXK3NkBpenN? MoT1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh5MkegZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFQvPzl7IN88UU4> MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
COR-L23 MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M13Pd|czKGi{cx?= NWrZOY5OT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hPS5|N{Og{txONg>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
A549 MojvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDWO|IhcHK| NITRdFlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTC1Mlk6OyEQvF2u MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1355 M3r6WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnfqO|IhcHK| MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF|NUWgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFYvPjh3IN88UU4> NUToRXlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H23 Mn3qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGTvNWI4OiCqcoO= NEWzOWpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA4NjF{NDFOwG0v MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1792 NIPETphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYS3NkBpenN? MkPqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzN{myJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA4NjNyNzFOwG0v MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1463 MnjNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVq3NkBpenN? Ml7YS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3cyPDZ|IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTC5MlczPSEQvF2u NGj0[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot p-GSK3 / GSK3 / p-PRAS40 / PRAS40 / p-FOXO / p-Casp9 / p-AKT / AKT / p-MEK / p-ERK / Erk ; ATG3 / ATG12 / LC3B 24978597 30867818
In vivo Mice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively.[1]

Protocol (from reference)

Kinase Assay:[1]
  • Potency (Ki*) of afuresertib:

    The true potency (Ki*) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ33P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2).

Cell Research:[1]
  • Cell lines: Hematological cell lines and solid tumor cell lines
  • Concentrations: 30 μM
  • Incubation Time: 72 h
  • Method: A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50’s are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.
Animal Research:[1]
  • Animal Models: Female athymic nude and SCID mice bearing SKOV3 or BT474 tumors
  • Dosages: 100 mg/kg
  • Administration: p.o.

Solubility (25°C)

In vitro

DMSO 85 mg/mL
(198.91 mM)
Ethanol 85 mg/mL
(198.91 mM)
Water Insoluble

Chemical Information

Molecular Weight 427.32
Formula

C18H17Cl2FN4OS

CAS No. 1047644-62-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04374630 Recruiting Drug: Paclitaxel|Drug: Afuresertib Platinum-resistant Ovarian Cancer Laekna Limited June 9 2020 Phase 2
NCT04060394 Recruiting Drug: Phase I and Phase II: LAE001/prednisone + afuresertib Metastatic Castration-resistant Prostate Cancer Laekna Limited September 13 2019 Phase 1|Phase 2
NCT02235740 Terminated Drug: Afuresertib|Drug: Carfilzomib Cancer Novartis|Amgen November 2014 Phase 1
NCT02240212 Completed Drug: Afuresertib|Drug: Paclitaxel Cancer Novartis Pharmaceuticals|Novartis October 2014 Phase 1
NCT02177682 Terminated Drug: Afuresertib Neoplasms Haematologic Novartis Pharmaceuticals|Novartis August 13 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Afuresertib (GSK2110183) | Afuresertib (GSK2110183) supplier | purchase Afuresertib (GSK2110183) | Afuresertib (GSK2110183) cost | Afuresertib (GSK2110183) manufacturer | order Afuresertib (GSK2110183) | Afuresertib (GSK2110183) distributor